Stable heterologous propagation CFTR protein variant cDNA

Details Stable heterologous propagation CFTR protein variant cDNA Stable heterologous propagation CFTR protein variant cDNA

1993-04-12

2000-05-16

Zitomer, Stephanie W.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 235, 4353201, C07H 2104

Patent

active

06063913&

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

This invention relates to modifications in the cDNA of full length cystic fibrosis transmembrane conductance regulator protein (CFTR) which facilitates propagation and/or expression in heterologous systems.


BACKGROUND OF THE INVENTION

Cystic fibrosis (CF) is the most common, life-threatening, autosomal recessive disease in the Caucasian population. Approximately 1 in 2,500 live births is affected by this genetic disorder. Obstructive lung disease, pancreatic enzyme insufficiency and elevated sweat electrolytes are the hallmarks for CF but the severity of these symptoms vary from patient to patient. Patients with CF usually die at an early age due to lung infection. With recent advances in clinical treatments, which are directed against the symptoms, the mean survival age for patients has increased to 26 years.
Despite intensive research efforts for the past fifty years, the basic defect in CF remains to be speculative. It is generally believed that the heavy mucus found in the respiratory tracts and the blockage of exocrine secretion from the pancreas are due to imbalance in water secretion which is the consequence of a defect in the regulation of ion transport in the epithelial cells.
The precise localization of the CF locus on the long arm of chromosome 7, region q31, facilitated the recent isolation of the responsible gene. The CF gene spans 250 kilobase pairs (kb) of DNA and encode a mRNA of about 6,500 nucleotides in length. The CFTR-gene is disclosed and claimed in U.S. application Ser. No. 401,609 filed Aug. 31, 1989. That application is co-owned by the applicant of this application.
Expression of this gene could be observed in a variety of tissues that are affected in CF patients, for example, lung, pancreas, liver, sweat gland and nasal epithelia. An open reading frame spanning 1480 amino acids could be deduced from the overlapping cDNA clones isolated. The putative protein as noted is called "Cystic Fibrosis Transmembrane Conductance Regulator" or CFTR for short, to reflect its possible role in the cells. The predicted molecular mass of CFTR is about 170,000.
Based on sequence alignment with other proteins of known functions, CFTR is thought to be a membrane-spanning protein which can function as a cyclic AMP-regulated chloride channel. The internal sequence identity between the first and second half of CFTR resembles the other prokaryotic and eukaryotic transport proteins, most notably, the mammalian P-glycoprotein.
The most frequent mutant allele of the CF gene involves a three base pair (bp) deletion which results in the deletion of a single amino acid residue (phenylalanine) at position 508, within the first ATP-binding domain of the predicted polypeptide. Although this mutation (.DELTA.F508) accounts for about 70% of all CF chromosomes, there is marked difference in its proportion among different populations. The remaining 30% of mutations in the CF gene appear to be heterogeneous and most of them are rare, with some represented by only single examples, as referenced in applicant's Canadian patent application filed Jul. 9, 1990.
The mutation screening study confirms that the ATP-binding domains detected by sequence alignment is important for CFTR function as multiple, different mutations have been found for many of the highly conserved amino acid residues in these regions. The locations of the various mutations also identified other functionally important regions in CFTR. There is, for example, a section three bp deletion resulting in the omission of an isoleucine residue at position 506 or 507 of the putative protein. While amino acid substitutions at these positions are apparently not disease-causing, this observation argues that the length of the peptide is more critical than the actual amino acid residue in the 506-508 region. Further, the existence of a large number of nonsense, frameshift as well as mRNA splicing mutations in the CF gene implies that absence of CFTR is not incompatible with life.
The varied symptoms among different CF patients suggest that di

REFERENCES:
patent: 4322274 (1982-03-01), Wilson et al.
patent: 4844893 (1989-07-01), Honsik et al.
patent: 4847201 (1989-07-01), Kaswasaki et al.
patent: 4853331 (1989-08-01), Herrnstadt et al.
patent: 4861589 (1989-08-01), Ju
patent: 4861719 (1989-08-01), Miller
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5240846 (1993-08-01), Collins et al.
"Correction of the Cystic Fibrosis Defect In Vitro by Retrovirus-Mediated Gene Transfer"; Drumm et al; pp. 1227-1233.
"Gamma-crystallins of the Human Eye Lens: Expression Analysis of Five Members of the Gene Family"; Meakin et al; pp. 2671-267.
"Lambda ZAP: a bacteriophage lambda expresion vector with in vivo excision properties"; Short et al; pp. 7583-7599.
"Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA"; Riordan et al; pp. 1066-1073.
Bear et al., Purification and Functional Reconstitution of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Cell 68:809-818 (1992).
Rommens et al., cAMP-Inducible Chloride Conductance in Mouse Fibroblast Lines Stably Expressing the Human Cystic Fibrosis Transmembrane Conductance Regulator, Proc. Natl. Acad. Sci. USA 88:7500-7504 (1991).
Kartner et al., Expression of the Cystic Fibrosis Gene in Non-Epithelial Invertebrate Cells Produces a Regulated Anion Conductance, Cell 64:681-691 (1991).
Zielenski et al., Genomic DNA Sequence of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene, Genomics 10:214-228 (1991).
Drumm et al., Correction of the Cystic Fibrosis Defect in Vitro by Retrovirus-Mediated Gene Transfer, Cell 62:1227-1233 (1990).
Quinton, P.M., Cystic Fibrosis: A Disease in Electrolyte Transport, FASEB J. 4:2709-2717 (1990).
The Cystic Fibrosis Genetic Analysis Consortium, Worldwide Survey of the .increment.F508 Mutation-Report from the Cystic Fibrosis Genetic Analysis Consortium, Am J. Hum. Genet. 47:354-359 (1990).
Venglarik et al., A Simple Assay for Agonist-Regulated Cl and K Conductances in Salt-Secreting Epithelial Cells, Am. J. Physiol. 259:C358-C364 (1990).
Kerem et al., Identification of Mutations in Regions Corresponding to the Two Putative Nucleotide (ATP)-Binding Folds of the Cystic Fibrosis Gene, Proc. Natl. Acad. Sci. USA 87:8447-8451 (1990).
Green et al., Chromosomal Region of the Cystic Fibrosis Gene in Yeast Artificial Chromosomes: A Model for Human Genome Mapping, Science 250:94-98 (1990).
Cliff et al., Separate Cl.sup.- Conductances Activated by cAMP and Ca.sup.2+ in Cl.sup.- -Secreting Epithelial Cells, Proc. Natl. Acad. Sci. USA 87:4956-4960 (1990).
Welsh, M.J. Abnormal Regulation of Ion Channels in Cystic Fibrosis Epithelia, FASEB J. 4:2718-2725 (1990).
Hyde et al., Structural Model of ATP-Binding Proteins Associated with Cystic Fibrosis, Multidrug Resistance and Bacterial Transport, Nature 346:362-365 (1990).
Cutting et al., A Cluster of Cystic Fibrosis Mutations in the First Nucleotide-Binding Fold of the Cystic Fibrosis Conductance Regulator Protein, Nature 346:366-369 (1990).
Slot et al., No Evidence for Expression of the Insulin-Regulatable Glucose Transporter in Endothelial Cells, Nature 346:369-371 (1990).
Dean et al., Multiple Mutations in Highly Conserved Residues are Found in Mildly Affected Cystic Fibrosis Patients, Cell 61:863-870 (1990).
Wilson, et al., Correction of CD18-Deficient Lymphocytes by Retrovirus-Mediated Gene Transfer, Science 248:1413-1416 (1990).
Schoumacher et al., A Cystic Fibrosis Pancreatic Adenocarcinom Cell Line, Proc. Natl. Acad. Sci. USA 87:4012-4016 (1990).
White et al., A Frame-Shift Mutation in the Cystic Fibrosis Gene, Nature 344:665-667 (1990).
Wilson et al., Expression of Human Adenosine Deaminase in Mice Reconstituted with Retrovirus-Transduced Hamatopoietic Stem Cells, Proc. Natl. Acad. Sci. USA 87:439-443 (1990).
Boat et al., Cystic Fibrosis in The Metabolic Basis of Inherited Disease, vol. II, (Scriver et al., eds.) McGraw-Hill Information Services Company, N.Y., N.Y., pp. 2649-2679 (1

Affiliated with

Also associated with

Rating

Stable heterologous propagation CFTR protein variant cDNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable heterologous propagation CFTR protein variant cDNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable heterologous propagation CFTR protein variant cDNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-259925